Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.69 Analyst target: $120.00 Upside: 17341.86%
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.